Standard BioTools Inc. (LAB) Dividend Safety
- Dividend payout ratio · 12 months: Value (m); Formula and calculation Cash dividends paid / net income. Period ending 2026-06-30..
Dividend safety
Overview →Financial period ending 2026-06-30; current quote (m). Amounts retain their stated periods and units.
| Metric | Value | Formula and calculation |
|---|---|---|
| Dividend payout ratio · 12 months | (m) | Cash dividends paid / net income. Period ending 2026-06-30. Calculation unavailable: missing inputs remain (m). |
Calculation inputs
| Input | Amount with unit | Raw financial data |
|---|---|---|
| Dividend payments · 12 months | (m) | |
| Net income · 12 months | 84.91M USD | Net Income (Loss) Attributable to Parent |
Calculated history
Changes compare with the next older row (previous quarter), unless explicitly labeled otherwise. Rolling 12-month growth compares two successive quarter-end rolling totals; it is not year-over-year growth.
| Period ending | Dividend payments · 12 months (USD) | Net income · 12 months (USD) | Dividend payout |
|---|---|---|---|
| 2026-06-30 | (m) | $84.91M | (m) |
| 2026-03-31 | (m) | $78.20M | (m) |
| 2025-12-31 | (m) | $-74.90M | (m) |
| 2025-09-30 | (m) | $-128.25M | (m) |
| 2025-06-30 | (m) | $-120.50M | (m) |
| 2025-03-31 | (m) | $-132.76M | (m) |
| 2024-12-31 | (m) | $-138.88M | (m) |
| 2024-09-30 | (m) | $-124.59M | (m) |
| 2024-06-30 | (m) | $-118.65M | (m) |
| 2024-03-31 | (m) | $-89.97M | (m) |
| 2023-12-31 | (m) | $-74.66M | (m) |
| 2023-09-30 | (m) | $-75.72M | (m) |
| 2023-06-30 | (m) | $-84.15M | (m) |
| 2023-03-31 | (m) | $-130.65M | (m) |
| 2022-12-31 | (m) | $-190.10M | (m) |
| 2022-09-30 | (m) | $-178.68M | (m) |
| 2022-06-30 | (m) | $-163.10M | (m) |
| 2022-03-31 | (m) | $-116.70M | (m) |
| 2021-12-31 | (m) | $-59.24M | (m) |
| 2021-09-30 | (m) | $-67.83M | (m) |
| 2021-06-30 | (m) | $-59.99M | (m) |
| 2021-03-31 | (m) | $-55.86M | (m) |
| 2020-12-31 | (m) | $-53.02M | (m) |
| 2020-09-30 | (m) | $-47.68M | (m) |
| 2020-06-30 | (m) | $-54.57M | (m) |
| 2020-03-31 | (m) | $-55.30M | (m) |
| 2019-12-31 | (m) | $-64.79M | (m) |
| 2019-09-30 | (m) | $-66.88M | (m) |
| 2019-06-30 | (m) | $-68.74M | (m) |
| 2019-03-31 | (m) | $-71.23M | (m) |
| 2018-12-31 | (m) | $-59.01M | (m) |
| 2018-09-30 | (m) | $-54.70M | (m) |
| 2018-06-30 | (m) | $-55.89M | (m) |
| 2018-03-31 | (m) | $-56.58M | (m) |
| 2017-12-31 | (m) | $-60.53M | (m) |
| 2017-09-30 | (m) | $-67.77M | (m) |
| 2017-06-30 | (m) | $-71.62M | (m) |
| 2017-03-31 | (m) | $-73.30M | (m) |
| 2016-12-31 | (m) | $-75.98M | (m) |
| 2016-09-30 | (m) | $-71.17M | (m) |
| 2016-06-30 | (m) | $-60.65M | (m) |
| 2016-03-31 | (m) | $-57.27M | (m) |
| 2015-12-31 | (m) | $-53.31M | (m) |
| 2015-09-30 | (m) | $-51.38M | (m) |
| 2015-06-30 | (m) | $-55.90M | (m) |
| 2015-03-31 | (m) | $-53.35M | (m) |
| 2014-12-31 | (m) | $-52.83M | (m) |
| 2014-09-30 | (m) | $-46.53M | (m) |
| 2014-06-30 | (m) | $-37.02M | (m) |
| 2014-03-31 | (m) | $-28.39M | (m) |
| 2013-12-31 | (m) | $-16.53M | (m) |
| 2013-09-30 | (m) | $-15.48M | (m) |
| 2013-06-30 | (m) | $-15.35M | (m) |
| 2013-03-31 | (m) | $-15.88M | (m) |
| 2012-12-31 | (m) | $-19.02M | (m) |
| 2012-09-30 | (m) | $-18.88M | (m) |
| 2012-06-30 | (m) | $-19.22M | (m) |
| 2012-03-31 | (m) | $-21.82M | (m) |
| 2011-12-31 | (m) | $-22.47M | (m) |
| 2011-09-30 | (m) | (m) | (m) |
| 2011-06-30 | (m) | (m) | (m) |
| 2011-03-31 | (m) | (m) | (m) |
| 2010-12-31 | (m) | $-16.90M | (m) |
| 2010-09-30 | (m) | (m) | (m) |
| 2010-06-30 | (m) | (m) | (m) |
| 2009-12-31 | (m) | (m) | (m) |
(m) means missing inputs. Historical market-based ratios use the saved close on or immediately before period ending and that period’s reported shares; current quotes are not substituted. Five-year projections repeat historical CAGR, not analyst forecasts.
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ROCKET PHARMACEUTICALS, INC. (RCKT) | United States | $0.296B | -21.78 |
| Vanda Pharmaceuticals Inc. (VNDA) | United States | $0.302B | -1.35 |
| Fulcrum Therapeutics, Inc. (FULC) | United States | $0.289B | -3.28 |
| Contineum Therapeutics, Inc. (CTNM) | United States | $0.289B | -4.40 |
| GT Biopharma, Inc. (GTBP) | United States | $0.309B | -4.58 |
| Perspective Therapeutics, Inc. (CATX) | United States | $0.284B | -3.34 |
| Upstream Bio, Inc. (UPB) | United States | $0.284B | -2.42 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Sagimet Biosciences Inc. (SGMT) | United States | $0.279B | |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |